The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
![](/xmlui/themes/Mirage2//images/mime.png)
Access
info:eu-repo/semantics/closedAccessDate
2018Author
Kılıçkap, SaadettinÖlmez, Ömer Fatih
Cicin, İrfan
Demirci, Umut
Alan, O.
Çabuk, Devrim
Sakalar, Teoman
Tatlı, Ali Murat
Buğdaycı, F. Başol
Eralp, Yeşim
Uysal, Mükremin
Demirkazik, Ahmet
Bilgin, Burak
Yıldız, Birol
Karaağaç, Mustafa
Okutur, Kerem
Sakin, Ayşegül
Metadata
Show full item recordCitation
Kılıçkap, S., Ölmez, Ö. F., Cicin, İ., Demirci, U., Alan, O., Çabuk, D. ... Sakin, A. (2018). The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey. 43rd ESMO Congress (ESMO) içinde (505-505. ss.). Munich, Germany, October 19-23, 2018.Abstract
…
WoS Q Kategorisi
Q1Source
43rd ESMO Congress (ESMO)Volume
29Issue
Supplement: 8Collections
- Bildiri Koleksiyonu [516]
- WoS İndeksli Yayınlar Koleksiyonu [6696]